Problems › Small Business Consulting Services › Healthcare Providers
The market for advice to practices managing value-based contracts is unregulated, with wide variation in quality, so the choice of adviser determines most of the outcome, yet referrals tend to favor personal compatibility over demonstrated skill with cost-per-episode analysis. What makes this harder for healthcare providers is structural: downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Any credible answer therefore has to hold cost per episode and payer mix in the same view, which is exactly where most internal analysis stops because the two live in different systems.
The market for advice to practices managing value-based contracts is unregulated, with wide variation in quality, so the choice of adviser determines most of the outcome, yet referrals tend to favor personal compatibility over demonstrated skill with cost-per-episode analysis. What makes this harder for healthcare providers is structural: downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Any credible answer therefore has to hold cost per episode and payer mix in the same view, which is exactly where most internal analysis stops because the two live in different systems.
The core difficulty is that the medical director or CFO purchasing this service lacks the internal data on cost per episode required to evaluate whether the advice will improve margins on the 38,000 attributed lives, and no standard credential confirms expertise in aligning payer mix with actual contribution per provider.
The recurring issues in these practices reduce to a few calculations from existing figures: whether certain service lines produce positive contribution per provider after full costs, if panel size growth is constrained by capacity or by contract terms, how the conversion cycle affects cash despite overall profitability under value-based contracts, and whether leadership time itself limits performance.
The pattern to avoid is the application of identical steps to every engagement without reference to the payer mix or cost-per-episode breakdowns, typically involving standardized recommendations on contract renegotiation, staff expansion, or system implementation that succeed only when the underlying constraint matches the intervention.
The diagnostic approach reviews the contribution per provider and cost per episode against the attributed lives under value-based contracts to identify which levers are open and what limits further progress, providing a lower-commitment step that informs whether ongoing support or an operational hire is the appropriate next move.
These three together are the signature. One on its own usually points somewhere else.
✓ The proposal outlines a fixed sequence of steps without first mapping the cost per episode across the current payer mix.
✓ Suggested changes to panel size or provider mix appear before any review of contribution per provider data.
✓ The adviser offers no examples of contracts where their prior guidance on value-based terms produced worse results than projected.
The move that usually makes it worse. Choosing based on personal connection from a referral, which predicts comfort during discussions but does not predict whether the guidance will match the specific constraints visible in the cost-per-episode and panel-size numbers.
It is for you if you run or finance a healthcare provider and the proposal describes a programme rather than a diagnosis. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Growth Strategy, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
For a defined piece of work — a pricing review, a profitability analysis, a growth diagnosis — £3k–£15k is the normal mid-market range and is usually enough. Open-ended monthly retainers of £1,500–£5,000 are common and are worth it only when there is ongoing delivery, not ongoing advice. If you are paying monthly for meetings, the meetings should be producing decisions you can name.
More often the latter than the market admits. A large share of small-business strategy questions are answered by disaggregating figures the business already produces but only ever looks at in total. If nobody has ever shown you contribution by product, by customer and by channel, that analysis is the first purchase and it is not expensive.
A coach works on the owner; a consultant works on the business. Coaching is about decisions you are avoiding, habits and accountability, and it genuinely helps some owners. Consulting is about what the right decision is. Confusing them is common, and paying consulting fees for accountability is the more expensive direction of the mistake.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · العربية · Tiếng Việt · ไทย · हिन्दी · עברית